BIIB Jan 2026 315.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 11:02AM EDT
Loading interactive chart…
- Benzinga
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
On Thursday, the European Commission granted marketing authorization under exceptional circumstances and maintained orphan designation for Biogen Inc’s (NASDAQ:BIIB) Qalsody (tofersen) for amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 gene (SOD1-ALS). Qalsody is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND). SOD1-ALS is an ultra-rare genetic form of ALS estimated to affe
- Zacks
Repligen (RGEN) Down 10.9% Since Last Earnings Report: Can It Rebound?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe
© 2024 Yahoo. All rights reserved.